01:02 PM EST, 11/06/2024 (MT Newswires) -- Genmab ( GMAB ) shares were down almost 2% in recent Wednesday trading after the company reported its Q3 results.

Earlier, the drugmaker posted Q3 diluted earnings of 19.81 Danish kroner ($2.85), down from 31.94 Danish kroner a year earlier.

Analysts polled by Capital IQ expected 21.63 Danish kroner.

Revenue for the quarter ended Sept. 30 was 5.54 billion Danish kroner, up from 4.71 billion Danish kroner a year earlier.

Analysts polled by Capital IQ expected 5.65 billion Danish kroner.

Genmab ( GMAB ) said it now expects 2024 revenue of 21.10 billion to 21.70 billion Danish kroner, compared with 20.50 billion to 21.70 billion kroner previously. Analysts expect 20.88 billion Danish kroner.

Price: 22.36, Change: -0.39, Percent Change: -1.71